Overview
This page compares Injective and RAY with live PEPS metrics. Rankings (#99 vs #180) and liquidity profiles differ, so traders often use them for distinct roles rather than as perfect substitutes.
Quick winners
Full comparison
| Metric | INJ | RAY |
|---|---|---|
| Price | $5.13 | $0.612800 |
| Market Cap | $490.41M | $164.93M |
| FDV | — | — |
| Volume 24h | $2.59M | $199,196.69 |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 180.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | RAY |
|---|---|---|
| 1H | — | — |
| 24H | +3.91% | +2.01% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | RAY |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.47 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 59.00 |
| Signal | neutral | neutral |
Automatic technical analysis
When RSI and trend disagree across Injective and RAY, expect choppy relative performance until one side reclaims a clear structure.
Fundamentals
| Metric | INJ | RAY |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
RAY
Pros and cons
Pros of Injective
- Higher ranking for Injective can translate into tighter spreads on major venues.
- Injective has an established coin page footprint on PEPS for continuous monitoring.
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- Composite PEPS readings for Injective can surface clearer module agreement during trend phases.
Cons of Injective
- Large-cap status for Injective can mean slower percentage upside versus high-beta alternatives.
- When dominance narratives fade, Injective can lag hotter rotation names.
- Crowded positioning around INJ sometimes amplifies squeeze or flush risk.
Pros of RAY
- Diversifying versus Injective with RAY can change portfolio factor exposure.
- PEPS tracking for RAY still includes AI score and level context for monitoring.
- Narrative optionality around RAY can reprice quickly when catalysts appear.
Cons of RAY
- Smaller book depth versus large caps can increase slippage for RAY.
- Weaker market-cap standing may leave RAY more exposed to liquidity droughts.
- Higher volatility on RAY cuts both ways and demands stricter risk limits.
Which looks stronger right now?
The “stronger” label here is descriptive, not predictive. Injective and RAY can alternate leadership as macro liquidity and narrative rotate.
AI summary
Comparing INJ and RAY begins with structure: capitalization, volume and rank. Present prints are $5.13 versus $0.612800. Momentum and trend can disagree with market-cap hierarchy. That is normal in crypto rotations and should be stress-tested against supports and news flow. Canonical URLs prevent duplicate RAY-vs-INJ pages, keeping SEO equity on one comparison. Keep monitoring winners as data updates.
FAQ
Which is better, Injective or RAY?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or RAY?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and RAY.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.